Trials / Terminated
TerminatedNCT00146029
Companion Pharmacogenetic Study to UMCC 9900/9901
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- —
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to examine the original breast tumor material to see how much of a metabolizing enzyme (CYP3A4) is present in tumor material. The researchers want to see if this is in any way associated with how the patient responded to docetaxel. They also want to examine the genes in the tumor that are responsible for the production of CYP metabolizing enzymes, to see if they are normal or if they have polymorphisms, or change compared to 'normal' CYP metabolizing enzymes.
Conditions
Timeline
- First posted
- 2005-09-05
- Last updated
- 2008-03-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00146029. Inclusion in this directory is not an endorsement.